Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(208)
•••
Post by scarlet1967on Jun 10, 2021 2:34pm
183 Views
Post# 33366186

NASH

NASH

The amount of patients suffering with the condition is sizeable enough for any approved drug to be a financial blockbuster.

  • 7 out of 10 people living with #type2diabetes in the U.S. also have nonalcoholic fatty liver disease (NAFLD). Learn more about the relationship between #T2D & #NAFLD.

 

  • While #obesity is strongly associated with #NAFLD/NASH, people who are not overweight can also have NAFLD/#NASH. Talk to your doctor about your risk factors and your options for screening and treatment. #NASHDay

 

  • An estimated 25–30% of people worldwide ???? currently have nonalcoholic fatty liver disease (#NAFLD) & 2–6% have nonalcoholic steatohepatitis (#NASH), the most severe form of NAFLD. Researchers estimate that the prevalence of #NASH could increase by over 50% by 2030. #NASHDay

 

  • Children with #obesity are at the greatest risk for developing pediatric #NAFLD and #NASH. Other factors, such as #type2diabetes, #insulin resistance, metabolic syndrome or high #cholesterol, can increase a child’s risk. #NASHDay

 

https://www.poz.com/article/honor-international-nash-day-2021your-liver-will-thank

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities